Company profile: UNION Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage pharmaceutical development of molecules with immunomodulatory and microbiological effects, focused on inflammatory skin disease and COVID-19. Developing Orismilast, a high-potency PDE4B/D inhibitor as an oral treatment for atopic dermatitis, hidradenitis suppurativa, psoriasis and ulcerative colitis, with Phase 2 studies (UCORIS in ulcerative colitis; IASOS in plaque psoriasis).
Products and services
- Orismilast: A high-potency PDE4 inhibitor targeting inflammation-linked PDE4B/D subtypes, engineered as an oral therapy for atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis
- IASOS Study: A Phase 2b study assessing efficacy and safety of orismilast in adult patients with moderate to severe plaque psoriasis
- UCORIS Study: An investigator-led study exploring efficacy and safety of orismilast in adult patients with moderate to severe ulcerative colitis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to UNION Therapeutics
Brii Biosciences
HQ: United States
Website
- Description: Provider of innovative medicines developed to improve public health in China, focusing on treatment options and preventive measures for Hepatitis B (prevention in Asia-Pacific excluding Japan), HIV therapies, NTM lung disease (Greater China rights), MDR/XDR Gram-negative bacterial infections (with Monash University), and anxiety and depressive disorders via internally discovered programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Brii Biosciences company profile →
Novira Therapeutics
HQ: United States
Website
- Description: Provider of antiviral drug discovery focused on first-in-class oral therapeutics targeting the viral capsid to treat chronic HBV and HIV infections, addressing diseases with high unmet need.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novira Therapeutics company profile →
Visby Medical
HQ: United States
Website
- Description: Provider of instrument-free PCR diagnostic tests for infectious disease detection, including the single-use Sexual Health Test that detects Chlamydia, Gonorrhea, and Trichomoniasis from self-collected vaginal swabs in under 30 minutes, and the Respiratory Health Test that detects and differentiates COVID-19, Influenza A, and Influenza B via nasopharyngeal swabs in under 30 minutes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Visby Medical company profile →
Evaxion Biotech
HQ: Denmark
Website
- Description: Provider of AI-immunology™ platform-driven immunotherapies for cancer and infectious diseases, including EVX-01, a Phase 2 personalized cancer vaccine targeting patient-specific tumor antigens, and EVX-B1, a vaccine antigen against Staphylococcus Aureus, plus models PIONEER™, ObsERV™, and AI-DEEP™ for vaccine design and CPI response prediction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Evaxion Biotech company profile →
Alverix
HQ: United States
Website
- Description: Provider of low-cost handheld reader devices with laboratory-grade accuracy and precision; partnering with diagnostic and OEM manufacturers to increase test accuracy, improve portability of existing tests, and develop new assays for use in physician offices and laboratory outreach.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alverix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for UNION Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to UNION Therapeutics
2.2 - Growth funds investing in similar companies to UNION Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for UNION Therapeutics
4.2 - Public trading comparable groups for UNION Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →